Sponsored by
This is an exciting new treatment. It is a next generation combination targeting 2 pathways:
1. an antiangiogenic drug - which blocks the formation of new blood vessels, which starves the tumor
2. Anti-invasion - so the tumor cells can't spread out looking for a new blood supply.
The Musella Foundation For Brain Tumor Research & Information, Inc has awarded a $30,000 research grant for the project titled:
Anti-Cancer Activity of OKN-007 in Pediatric Gliomas. This is an experimental treatment that stops 2 growth mechanisms: it stops the formation of new blood vessels, and it also stops invasion. Earlier work on an adult glioblastoma rat model looked very good so a human recurrent adult high grade glioma trial has started. Our project will pay for the pre-clinical work using this new drug on a pediatric glioma rat model, to pave the way for a pediatric brain tumor trial! There are more details about the treatment at:
http://newsok.com/omrf-researchers-finding-some-hope-in-anti-brain-tumor-drug/article/3809147